{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["59(7)"],"submitter":["Jonsson KL"],"pubmed_abstract":["Adjunct therapy with the histone deacetylase inhibitor (HDACi) romidepsin increases plasma viremia in HIV patients on combination antiretroviral therapy (cART). However, a potential concern is that reversing HIV latency with an HDACi may reactivate the virus in anatomical compartments with suboptimal cART concentrations, leading to de novo infection of susceptible cells in these sites. We tested physiologically relevant romidepsin concentrations known to reactivate latent HIV in order to definitively address this concern. We found that romidepsin significantly inhibited HIV infection in peripheral blood mononuclear cells and CD4(+) T cells but not in monocyte-derived macrophages. In addition, romidepsin impaired HIV spreading in CD4(+) T cell cultures. When we evaluated the impact of romid"],"journal":["Antimicrobial agents and chemotherapy"],"pagination":["3984-94"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4468708"],"repository":["biostudies-literature"],"pubmed_title":["Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections."],"pmcid":["PMC4468708"],"pubmed_authors":["Denton PW","Laustsen A","Ostergaard L","Tolstrup M","Jonsson KL","Vad-Nielsen J","Sogaard OS","Kjær K","Rasmussen TA","Andersen MN","Jakobsen MR"],"additional_accession":[]},"is_claimable":false,"name":"Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.","description":"Adjunct therapy with the histone deacetylase inhibitor (HDACi) romidepsin increases plasma viremia in HIV patients on combination antiretroviral therapy (cART). However, a potential concern is that reversing HIV latency with an HDACi may reactivate the virus in anatomical compartments with suboptimal cART concentrations, leading to de novo infection of susceptible cells in these sites. We tested physiologically relevant romidepsin concentrations known to reactivate latent HIV in order to definitively address this concern. We found that romidepsin significantly inhibited HIV infection in peripheral blood mononuclear cells and CD4(+) T cells but not in monocyte-derived macrophages. In addition, romidepsin impaired HIV spreading in CD4(+) T cell cultures. When we evaluated the impact of romid","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Jul","modification":"2025-04-04T11:08:10.847Z","creation":"2019-03-27T01:53:31Z"},"accession":"S-EPMC4468708","cross_references":{"pubmed":["25896701"],"doi":["10.1128/AAC.00574-15","10.1128/aac.00574-15"]}}